Shubhshree Biofuels Energy Ltd received clean audit opinions for FY2025-26, yet the underlying audit reports carry repeated adverse findings across two years. Working capital returns filed with banks do not match the company's books, loans to subsidiaries lack repayment terms, and all three subsidiaries drew adverse audit remarks in FY2025. The group also faces regulatory penalties, governance churn, and negative operating cash flow.
Key findings
- Clean opinions mask repeated CARO adverse findings
Major- Khandelwal Badaya & Co. issued unmodified opinions for FY2025-26, with no fraud reported. Yet CARO clause 3(ii) states monthly returns filed with banks on primary security do not agree with books for working capital limits above ₹5 crore in both FY2025-26 and FY2024-25. All three subsidiaries, Shubh Shree Recycling, Rural Green Energy, and Ecodensify Solutions, carried an adverse remark under Clause 3(xvii) in FY2024-25. - Loans to director-interested entities lack repayment terms
Major- The auditor reported that 100% of loans granted to subsidiaries and associates carried no specified repayment terms, and could not comment on regularity, overdue amounts, or fallen-due loans. Shareholder resolutions authorize up to ₹10 crore per related entity, including Agrizen Bioenergy LLP and Biosteam LLP, where directors are interested. For subsidiary loans, interest rates and repayment schedules are stated as "tentative and indicative in nature". - Promoter family controls key posts with CFO churn and holding decline
Major- The CMD is spouse of a Non-executive Director and brother of the Whole-time Director. Three CFO changes occurred in one year: Kumawat resigned June 21, 2025, Goyanka appointed June 22 and resigned October 13, 2025, Kumawat re-appointed October 14, 2025. Promoter holding fell 26.42 percentage points to 73.58% in one year, and a Designated Person's relative executed a contra trade, drawing a ₹23,000 penalty. - Operating cash flow negative for two years with unfunded capex plan
Major- CFO was -₹1.13 crore in FY26 and -₹8.67 crore in FY25, against PAT of ₹11.06 crore and ₹8.09 crore. Management plans ₹15-20 crore capex in FY27 to raise capacity from 450 to 1,000 metric tons per day, with funding "in the planning phase" and no timeline. Management declined to provide the full-year FY26 capex figure despite stating H2 capex of around ₹4 crore. - Rapid 12-month group build-out with inconsistent disclosure
Major- The company incorporated three subsidiaries and two associate LLPs during FY2025-26. The Board's Report states "no associate companies," while the same report's AOC-1 and secretarial audit disclose Agrizen Bioenergy LLP and Biosteam LLP as associates. The principal auditor did not audit any subsidiary's financials, and one subsidiary's share capital remained unpaid "due to banking difficulties". - Repeated NSE penalties and compliance lapses
Major- NSE fined the company ₹1,77,000 for late submission of consolidated results for the half year ended March 31, 2025, and ₹1,53,400 for a similar Regulation 33 breach. The secretarial audit flagged delayed entries in the Structured Digital Database and a contra trade by a Designated Person's relative. NSE also issued a warning for disclosing a promoter group member's PAN in February 2025 disclosures. - Revenue quality unverifiable, receivables unconfirmed, customers unquantified
Major- The auditor could not independently verify trade receivables and payables balances due to non-availability of confirmations, though the opinion was not modified. Management named PepsiCo, Coca-Cola, and Dabur India as customers but gave no revenue contribution or concentration data. The FY2024-25 MD&A itself discloses "high client concentration" as a risk.
What to watch
- AGM votes on related-party loans. Shareholders vote on Section 185 loans to Biosteam LLP up to ₹10 crore and material RPTs with subsidiaries for FY2028-FY2030 at the FY2025-26 AGM.
- Director re-appointments. Shareholders vote on re-appointing Sagar Agrawal as CMD and Anurag Agarwal as WTD for three years from March 16, 2027.
- Capex funding plan. Management committed to make the funding plan public "within this week" as of the Q4 FY26 transcript (March 2026); no announcement had been made.
- CARO working-capital mismatch. Watch whether the clause 3(ii) adverse finding on bank returns vs books continues in the FY27 audit report.
- Associate disclosure contradiction. Watch whether the FY2026-27 annual report resolves the conflict between "no associates" in the Board's Report and two associates in AOC-1.
Bottom line: This is a fast-growing company with a clean audit opinion, but the record beneath it is heavily qualified. The core risk is that reported revenue and working capital cannot be independently verified, bank statements don't match books, receivables are unconfirmed, and related-party loans carry no repayment discipline. The group is expanding quickly while cash flow is negative and the funding plan is undisclosed; the AGM votes and the FY27 audit report will show whether these gaps close.